← Leaderboards
Nicholas James Lawrence
H. Lee Moffitt Cancer Ctr & Res Inst
$847,789
Attributed
$1,695,578
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $355.8K · FY2009–13$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$1,695,578 · 1
By mechanism
R01$1,695,578 · 1
Top collaborators
- Said M Sebti5 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Eric B. Haura$11,744,471
- Harshani R Lawrence$3,059,505
- Gary W Reuther$4,321,756
- Paulo Cesar Rodriguez$11,501,509
- David Shibata$3,836,288
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisAnimal ModelAnti-Cancer TherapeuticAntineoplastic AgentsApoptosisApoptosis InhibitorApoptoticApplications GrantsBaseBinding (Molecular Function)Binding ProteinsBiological AvailabilityBiological ProcessCancer CellCancer EtiologyCancer TherapyCell DeathCell GrowthCell NucleusCell ProliferationCellsChemotherapyC-Myc Staining MethodCollaborations
Grant awards (5)
Targeting STAT3 as a novel approach to cancer therapy$315,201
R01 · FY2013 · CA
Targeting STAT3 as a novel approach to cancer therapy$336,674
R01 · FY2012 · CA
Targeting STAT3 as a novel approach to cancer therapy$338,920
R01 · FY2011 · CA
Targeting STAT3 as a novel approach to cancer therapy$355,838
R01 · FY2010 · CA
Targeting STAT3 as a novel approach to cancer therapy$348,945
R01 · FY2009 · CA